155 - Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study

Presenting Author(s)

• 

  Onyema Ogbuagu, MD

  Associate Professor and Director, Antivirals and vaccines research Program
  Yale School of Medicine
  Cheshire, CT, United States

  Slides

Co-Author(s)

• JM

  Joseph P. McGowan, MD

  Center for AIDS Research and Treatment
  Manhasset, New York, United States
• AS

  Ann Stapleton, MD

  Rimrock Clinic, Eisenhower Health
  Rancho Mirage, California, United States
• AW

  Andrew Wiznia, MD

  Jacobi Medical Center, Albert Einstein College of Medicine
  Bronx, New York, United States
• DB

  Daniel Berger, MD

  Practicing Physician
  Northstar Medical Center
  Chicago, Illinois, United States
• CC

  Catherine M. Creticos, MD

  Howard Brown Health
  Chicago, Illinois, United States
• 

  Debbie P. Hagins, MD, FAPCR, AAHIVS

  Family Medicine Specialist
  Georgia Department of Public Health, Coastal Health District, Chatham CARE Center, Savannah, GA, USA
  Savannah, Georgia, United States
• 

  Olayemi Osiyemi, MD

  President
  Triple O Research Institute
  West Palm Beach, Florida, United States
• JS

  James Sims, MD

  St Hope Foundation
  Houston, Texas, United States
• DW

  David A. Wheeler, MD

  Infectious Diseases Physicians, Inc.
  Annandale, Virginia, United States
• HW

  Hui Wang, PhD

  Gilead Sciences Inc.
  Foster City, California, United States
• NM

  Nicolas A. Margot, MA

  Senior Research Scientist
  Gilead Sciences Inc.
  Foster City, California, United States
• HD

  Hadas Dvory-Sobol, PhD

  Gilead Sciences
  Foster City, California, United States
• MR

  Martin Rhee, MD

  Gilead Sciences
  Foster City, California, United States
• SS

  Sorana Segal-Maurer, MD

  Division of Infectious Diseases, New York–Presbyterian Queens
  Flushing, New York, United States